Furthermore, it has been proposed that by understanding the mechanism of response for NF1-PN, the development of rational combinations of MEK inhibitors with other targeted or cytotoxic therapies may be possible [83]. This evidence concerns the gene MAP2K7 and poikiloderma with neutropenia.